Immunotherapies that mobilize a patient’s own immune system to fight cancer have become a treatment pillar. These therapies, including CAR T-cell therapy, have performed well in cancers like leukemias and lymphomas, but the results have been less promising in solid tumors.
Gut microbe metabolite found to modulate heart disease risk through β2-adrenergic receptors
Study identifies phenylacetylglutamine (PAGln), a gut microbiome metabolite, as a novel allosteric modulator of β2-adrenergic receptors, offering insights into its role in cardiovascular disease (CVD)